{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:06:13Z","timestamp":1793297173475,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014471","name":"Mundipharma Research Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Candida species are responsible for fungal diseases and the development of nosocomial bloodstream infections. Treatment is resource-intensive and economically challenging for healthcare systems. Cost analyses of drugs against candidiasis, such as rezafungin, are thus of great interest to healthcare payers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a cost-of-illness study of patients with Candida infections based on real-word data of the Department I of Internal Medicine, University Hospital Cologne (Germany) between 2016 and 2021. Health-economic parameters were analysed to describe the economic impact of Candida infections. Potential cost savings due to the administration of rezafungin were modelled for patients with invasive candidiasis or candidaemia based on a 5\u2005day reduction of ICU length of stay (LOS) shown by the STRIVE study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found 724 cases (652 patients) with Candida infections, of which 61% received ICU treatment (n\u200a=\u200a442) and 29% were mechanically ventilated (n\u200a=\u200a207). Twenty-six percent died during hospitalization (n\u200a=\u200a185). Median LOS was 25 and 15\u2005days, on normal wards and ICU, respectively. Median total treatment costs per case accounted for \u20ac22\u200a820. Based on the ICU LOS reduction, the retrospective model showed a median cost-saving potential of \u20ac7175 per hospital case with invasive candidiasis or candidaemia. Accumulated cost savings for 37 patients of \u20ac283\u200a335 were found.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment of candidiasis is cost intensive due to increased hospital LOS. The ICU LOS reduction rezafungin showed in STRIVE would lead to sustainable cost savings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlad079","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T21:19:46Z","timestamp":1687209586000},"source":"Crossref","is-referenced-by-count":22,"title":["Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis"],"prefix":"10.1093","volume":"5","author":[{"given":"Julia","family":"Jeck","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne , Kerpener Stra\u00dfe 62, 50937 Cologne , Germany"},{"name":"VITIS GmbH , Am Morsdorfer Hof 12, 50933 Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Jakobs","sequence":"additional","affiliation":[{"name":"Department of Haematology and Stem Cell Transplantation, Faculty of Medicine and Essen University Hospital, University of Duisburg-Essen , Hufelandstra\u00dfe 55, 45147 Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina S","family":"Kurte","sequence":"additional","affiliation":[{"name":"VITIS GmbH , Am Morsdorfer Hof 12, 50933 Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne , Kerpener Stra\u00dfe 62, 50937 Cologne , Germany"},{"name":"Center for Integrated Oncology Cologne (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne , Kerpener Stra\u00dfe 28 62, 50937 Cologne , Germany"},{"name":"Clinical Trials Centre Cologne (ZKS K\u00f6ln), Faculty of Medicine and University Hospital Cologne, University of Cologne , Gleueler Stra\u00dfe 269, 50935 Cologne , Germany"},{"name":"CECAD Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine and University Hospital Cologne, University of Cologne , Joseph-Stelzmann-Stra\u00dfe 26, 50931 Cologne , Germany"},{"name":"Excellence Centre for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne , Kerpener Stra\u00dfe 62, 50937 Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kron","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne , Kerpener Stra\u00dfe 62, 50937 Cologne , Germany"},{"name":"VITIS GmbH , Am Morsdorfer Hof 12, 50933 Cologne , Germany"},{"name":"Center for Integrated Oncology Cologne (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne , Kerpener Stra\u00dfe 28 62, 50937 Cologne , Germany"},{"name":"FOM University of Applied Sciences , Leimkugelstra\u00dfe 6, 45141 Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"issue":"Suppl","key":"2023061920192281600_dlad079-B1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0195-6701(95)90036-5","article-title":"Epidemiology of candidiasis","volume":"30","author":"Pfaller","year":"1995","journal-title":"J Hosp Infect"},{"key":"2023061920192281600_dlad079-B2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2174\/138945006776359421","article-title":"Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts","volume":"7","author":"Ruhnke","year":"2006","journal-title":"Curr Drug Targets"},{"key":"2023061920192281600_dlad079-B3","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/clinids\/20.6.1526","article-title":"Epidemiology of nosocomial fungal infections, with emphasis on Candida species","volume":"20","author":"Jarvis","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2023061920192281600_dlad079-B4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.idc.2006.07.004","article-title":"Invasive candidiasis","volume":"20","author":"Pappas","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"2023061920192281600_dlad079-B5","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/archinte.1989.00390100145030","article-title":"Risk factors for hospital-acquired candidemia. A matched case-control study","volume":"149","author":"Wey","year":"1989","journal-title":"Arch Intern Med"},{"key":"2023061920192281600_dlad079-B6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/TCRM.S40160","article-title":"Epidemiology and risk factors for invasive candidiasis","volume":"10","author":"Yapar","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"2023061920192281600_dlad079-B7","author":"Groll"},{"issue":"Suppl 7","key":"2023061920192281600_dlad079-B8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023061920192281600_dlad079-B9","author":"EMA"},{"key":"2023061920192281600_dlad079-B10","author":"US FDA"},{"key":"2023061920192281600_dlad079-B11","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023061920192281600_dlad079-B12","article-title":"40th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 2021","author":"Soriano"},{"key":"2023061920192281600_dlad079-B13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/2047-783X-16-4-180","article-title":"Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature","volume":"16","author":"Wilke","year":"2011","journal-title":"Eur J Med Res"},{"key":"2023061920192281600_dlad079-B14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijantimicag.2013.08.010","article-title":"Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives","volume":"43","author":"Neoh","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2023061920192281600_dlad079-B15","author":"State law of North Rhine-Westphalia"},{"key":"2023061920192281600_dlad079-B16","author":"German Institute for Quality and Efficiency in Health Care"},{"key":"2023061920192281600_dlad079-B17","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte"},{"key":"2023061920192281600_dlad079-B18","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte"},{"key":"2023061920192281600_dlad079-B19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vhri.2019.07.002","article-title":"The economic burden of candidemia and invasive candidiasis: a systematic review","volume":"21","author":"Ismail","year":"2020","journal-title":"Value Health Reg Issues"},{"key":"2023061920192281600_dlad079-B20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mycmed.2013.05.004","article-title":"Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain","volume":"23","author":"Grau","year":"2013","journal-title":"J Mycol Med"},{"key":"2023061920192281600_dlad079-B21","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/jac\/dkr186","article-title":"Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis","volume":"66","author":"Neoh","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2023061920192281600_dlad079-B22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/s12879-015-1143-1","article-title":"Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis","volume":"15","author":"Auzinger","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2023061920192281600_dlad079-B23","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1185\/03007990903072565","article-title":"Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK","volume":"25","author":"Sidhu","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2023061920192281600_dlad079-B24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/ajrccm.156.2.9612023","article-title":"Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study","volume":"156","author":"El-Ebiary","year":"1997","journal-title":"Am J Respir Crit Care Med"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/3\/dlad079\/50646801\/dlad079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/3\/dlad079\/50646801\/dlad079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T21:19:58Z","timestamp":1687209598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlad079\/7202276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlad079","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,5,3]]},"article-number":"dlad079"}}